Home

Incyte Corporation - Common Stock (INCY)

60.34
+0.34 (0.57%)

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with serious diseases, particularly cancer and other unmet medical needs

The company leverages its expertise in molecular biology and drug development to create targeted treatments that aim to improve patient outcomes. With a strong emphasis on research and clinical trials, Incyte strives to advance its pipeline of potential medications, which includes both its proprietary compounds and collaborations with other pharmaceutical partners. Through its commitment to scientific excellence and patient-centric approaches, Incyte aims to address significant healthcare challenges and enhance the quality of life for individuals suffering from complex conditions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close60.00
Open60.37
Bid59.20
Ask61.24
Day's Range59.92 - 61.15
52 Week Range50.35 - 83.95
Volume2,323,185
Market Cap13.42B
PE Ratio (TTM)301.70
EPS (TTM)0.2
Dividend & YieldN/A (N/A)
1 Month Average Volume1,843,868

News & Press Releases

Tesla To $320? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · March 18, 2025
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesdaybenzinga.com
Via Benzinga · March 18, 2025
What's going on in today's after hours session: S&P500 moverschartmill.com
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
Via Chartmill · March 17, 2025
Stay informed with the top movers within the S&P500 index on Monday.chartmill.com
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.
Via Chartmill · March 17, 2025
Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)benzinga.com
Via Benzinga · March 11, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · March 17, 2025
Why Incyte (INCY) Stock Is Nosediving
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment, which fell below Wall Street's expectations. According to the data, the drug was effective for less than half of the participants who took it in the trials.
Via StockStory · March 17, 2025
Gapping S&P500 stocks in Monday's sessionchartmill.com
Let's have a look at what is happening on the US markets on Monday. Below you can find the S&P500 gap up and gap down stocks in today's session.
Via Chartmill · March 17, 2025
These S&P500 stocks are moving in today's pre-market sessionchartmill.com
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Via Chartmill · March 17, 2025
Which stocks are moving before the opening bell on Monday?chartmill.com
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · March 17, 2025
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Fallsbenzinga.com
Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.
Via Benzinga · March 17, 2025
Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive'investors.com
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as shares fell.
Via Investor's Business Daily · March 17, 2025
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 17, 2025
Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag.chartmill.com
Take a closer look at INCYTE CORP , a remarkable value stock. NASDAQ:INCY excels in fundamentals and maintains a very reasonable valuation.
Via Chartmill · March 17, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 17, 2025
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · March 17, 2025
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
By Incyte · Via Business Wire · March 17, 2025
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Lossbenzinga.com
Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks.
Via Benzinga · March 11, 2025
Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumpsbenzinga.com
Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary endpoint fell short.
Via Benzinga · March 10, 2025
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 – Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando.
By Incyte · Via Business Wire · March 8, 2025
These S&P500 stocks are moving in today's pre-market sessionchartmill.com
The US market session of Friday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via Chartmill · March 7, 2025
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 13,351 shares of the Company’s common stock to 16 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of March 3, 2025, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
By Incyte · Via Business Wire · March 7, 2025
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · March 3, 2025
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · March 3, 2025
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando.
By Incyte · Via Business Wire · February 28, 2025